Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 172,892
  • Shares Outstanding, K 66,497
  • Annual Sales, $ 20,440 K
  • Annual Income, $ -91,140 K
  • 60-Month Beta 1.83
  • Price/Sales 8.35
  • Price/Cash Flow N/A
  • Price/Book 9.09
Trade XERS with:

Options Overview

Details
  • Implied Volatility 97.14%
  • Historical Volatility 73.54%
  • IV Percentile 26%
  • IV Rank 23.97%
  • IV High 226.11% on 06/03/21
  • IV Low 56.48% on 07/30/21
  • Put/Call Vol Ratio 0.17
  • Today's Volume 194
  • Volume Avg (30-Day) 1,393
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 37,203
  • Open Int (30-Day) 37,413

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.39
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +2.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.16 +20.37%
on 08/20/21
3.08 -15.58%
on 08/26/21
+0.34 (+15.04%)
since 08/17/21
3-Month
2.16 +20.37%
on 08/20/21
4.98 -47.79%
on 06/25/21
-1.48 (-36.27%)
since 06/17/21
52-Week
2.16 +20.37%
on 08/20/21
7.94 -67.25%
on 02/08/21
-3.13 (-54.62%)
since 09/17/20

Most Recent Stories

More News
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that...

XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) ("Xeris") today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP)...

SBBP : 2.12 (+1.44%)
XERS : 2.60 (+2.77%)
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

Strongbridge Biopharma plc (NASDAQ: SBBP) (the "Company" or "Strongbridge") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by...

SBBP : 2.12 (+1.44%)
XERS : 2.60 (+2.77%)
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris

Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote "FOR" Transaction with Xeris

SBBP : 2.12 (+1.44%)
XERS : 2.60 (+2.77%)
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeris

Strongbridge Biopharma plc (Nasdaq: SBBP) ("Strongbridge") today announced that the leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Strongbridge...

SBBP : 2.12 (+1.44%)
XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote "FOR" the Transaction With Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Xeris stockholders vote "FOR" all...

SBBP : 2.12 (+1.44%)
XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke(R) Kit for the Treatment of Severe Hypoglycemia

--Gvoke HypoPen(R), Gvoke(R) PFS, and Gvoke(R) Kit - three different administration options to accommodate patients' preferences

XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Strengthens Its Patent Estate

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Achieves Unprecedented Levels of Payor Coverage for Gvoke(R)

--3 million Illinois Medicaid lives to be added effective Oct 1st

XERS : 2.60 (+2.77%)
Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol(TM) Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 2.60 (+2.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 2.79
2nd Resistance Point 2.69
1st Resistance Point 2.65
Last Price 2.60
1st Support Level 2.51
2nd Support Level 2.41
3rd Support Level 2.37

See More

52-Week High 7.94
Fibonacci 61.8% 5.73
Fibonacci 50% 5.05
Fibonacci 38.2% 4.37
Last Price 2.60
52-Week Low 2.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar